{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"semax-chemo-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/semax-chemo-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"semax-chemo-neuropathy","title":"Semax for Chemotherapy-Induced Neuropathy: Evidence Review","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:52.279Z","body_excerpt":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy-induced peripheral neuropathy develops when certain chemo agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids commonly trigger this. Sensory axons in a stocking-glove distribution degenerate first. Axonal transport slows. Mitochondrial function in neurons drops. Inflammatory signals rise around the nerves. Pain, tingling, numbness, and balance problems follow. The process is degenerative: damage outpaces the nerves' natural repair capacity. Some symptoms improve after chemo ends, but many persist for months or years because repair pathways stay under-activated.\n\nBDNF supports neuron survival, axon maintenance, and synaptic repair. Levels can fall during chemo stress and recovery. If your CIPN includes slowed nerve regeneration or lingering sensory deficits, that layer of breakdown matters for any discussion of repair-focused compounds.\n\n## Why Semax might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **What keeps failing:** BDNF decline, nerve stress from chemo agents, slowed axon repair and sensory signaling after treatment.\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\nSemax has been examined mainly in stroke and optic-nerve contexts for its effects on BDNF expression. If your CIPN involves reduced neurotrophic support, the peptide's studied actions on BDNF transcription and neuron survival pathways align with repair rather than symptom suppression.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain intensity and improve daily function while nerves remain damaged. That helps quality of life but does not address the underlying axonal degeneration or support regeneration. Using it trades ongoing symptom control for time during which repair pathways would need separate activation.\n\n## How these fit together\n\nSingle-compound focus — Semax targets the neural / cognitive repair layer. Gabapentin / pregabalin addresses symptom load through signal suppression. They operate on different parts of the problem: one studied for potential support of BDNF-driven repair, the other for immediate pain gating. No overlap in mechanism means they could be considered together only if both layers need attention, without one replacing the other.\n\n## What the evidence actually shows\n\nNo human trials test Semax specifically in chemotherapy-induced peripheral neuropathy (preclinical/mechanistic). Semax increases BDNF mRNA and protein in rat hippocampus and cortex after ischemia models (preclinical). One small human study in ischemic stroke patients found Semax raised plasma BDNF and improved motor scores when added to rehabilitation (human). Semax showed neuroprotective effects in rat optic-nerve models and one small open-label human series on glaucomatous optic neuropathy (preclinical + human, small). Commercial sites mention possible benefit in non-proliferative diabetic neuropathy without published trial data (anecdotal/mechanistic).\n\nCIPN itself has large observational data: prevalence reaches 68 % at one month post-chemo, falling to 30 % at six months (human epidemiology). No Semax data exist in that population.\n\n## What scientists say\n\nResearchers describe Semax as an ACTH(4-10) analog that modulates neurotrophin expression. Animal work links it to faster BDNF induction after hypoxic or ischemic stress. Human stroke rehabilitation data remain limited to Russian-language reports. No peer-reviewed CIPN-specific conclusions appear in Western lite","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c4","text":"CIPN prevalence reaches 68% one month after neurotoxic chemotherapy and declines to 30% by six months.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["web:1","web:0"],"source_status":"sourced","why_material":"Quantifies the scale of the condition independent of any compound.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c1","text":"No published human trials examine Semax in chemotherapy-induced peripheral neuropathy.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["web:0","web:1"],"source_status":"sourced","why_material":"Establishes the evidence gap for this specific condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c3","text":"A small human study found Semax raised plasma BDNF and improved motor outcomes in ischemic stroke patients during rehabilitation.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["web:27"],"source_status":"sourced","why_material":"Provides the only direct human BDNF data for Semax.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"Semax increases BDNF mRNA and protein expression in rat brain after ischemia models.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["web:19"],"source_status":"sourced","why_material":"Supports the mechanistic link to neural repair pathways.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"One Reddit user with small-fiber neuropathy reported subjective sensory changes after first use of Semax nasal spray.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["web:9"],"source_status":"sourced","why_material":"Documents the only publicly available user report linking Semax to neuropathy symptoms.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"web:0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5656281/","title":"Chemotherapy-Induced Peripheral Neuropathy - PMC - NIH","quote":"Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer.","summary":"Overview of CIPN prevalence and mechanisms.","claim_ids":["c1","c4"],"link_status":"ok","quote_status":"verified","hash":"703288155209fdbd9aa2f04c48515ff1567152d5bee635e591f07a9ffc636864"},{"id":"web:1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","summary":"Epidemiology and persistence data for CIPN.","claim_ids":["c4","c1"],"link_status":"ok","quote_status":"unverified","hash":"c731febd87f1c4f14d8ca296f3e7bb4d97bf56fcd276ef0f9c89d98507e3c02a"},{"id":"web:19","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/","title":"Semax and Pro-Gly-Pro Activate the Transcription of ...","quote":"It has been suggested that the neuroprotective effects of Semax are related to neurotrophin gene expression: the rapid induction of Bdnf and Ngf mRNAs in rat ...","summary":"Rat data on Semax and BDNF induction.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"ff7f4e55aee7e6ce43cba9c52075966774a10f6ea288e0f58d20ba263fa48524"},{"id":"web:27","type":"other","url":"https://www.researchgate.net/publication/325375504_The_efficacy_of_semax_in_the_tretament_of_patients_at_different_stages_of_ischemic_stroke","title":"The efficacy of semax in the tretament of patients at different stages of ischemic stroke","quote":"Administration of semax and high BDNF levels accelerated the improvement and ameliorated the final outcome of Barthel score index.","summary":"Small human stroke study with Semax and BDNF.","claim_ids":["c3"],"link_status":"http_403","quote_status":"unverified","hash":"f414c8798a6af6ad098bdce8070fe42994218037da1c8fa827261654cb6d44a3"},{"id":"web:9","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1ds2bl5/semax/","title":"Semax : r/smallfiberneuropathy","quote":"I decided to try a nootropic nasal spray called Semax (peptide based) which is a russian stroke treatment. At night on the day I first started using it I ...","summary":"User anecdote on Semax and neuropathy symptoms.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"597464a8946f7b9412776190491cf271adb731cbfb5de8fe0fa54b271499ef2d"}],"anecdotal_sources":[{"id":"web:9","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1ds2bl5/semax/","title":"Semax : r/smallfiberneuropathy","quote":"I decided to try a nootropic nasal spray called Semax (peptide based) which is a russian stroke treatment. At night on the day I first started using it I ...","summary":"User anecdote on Semax and neuropathy symptoms.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"597464a8946f7b9412776190491cf271adb731cbfb5de8fe0fa54b271499ef2d"}],"scientific_sources":[{"id":"web:0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5656281/","title":"Chemotherapy-Induced Peripheral Neuropathy - PMC - NIH","quote":"Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer.","summary":"Overview of CIPN prevalence and mechanisms.","claim_ids":["c1","c4"],"link_status":"ok","quote_status":"verified","hash":"703288155209fdbd9aa2f04c48515ff1567152d5bee635e591f07a9ffc636864"},{"id":"web:1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","summary":"Epidemiology and persistence data for CIPN.","claim_ids":["c4","c1"],"link_status":"ok","quote_status":"unverified","hash":"c731febd87f1c4f14d8ca296f3e7bb4d97bf56fcd276ef0f9c89d98507e3c02a"},{"id":"web:19","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/","title":"Semax and Pro-Gly-Pro Activate the Transcription of ...","quote":"It has been suggested that the neuroprotective effects of Semax are related to neurotrophin gene expression: the rapid induction of Bdnf and Ngf mRNAs in rat ...","summary":"Rat data on Semax and BDNF induction.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"ff7f4e55aee7e6ce43cba9c52075966774a10f6ea288e0f58d20ba263fa48524"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"semax-chemo-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":5,"anecdotal":1,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}